National Institute on Drug Abuse, Division of Therapeutics and Medical Consequences, USA.
National Institute on Drug Abuse, Division of Therapeutics and Medical Consequences, USA.
Prev Med. 2023 Nov;176:107650. doi: 10.1016/j.ypmed.2023.107650. Epub 2023 Jul 29.
The purpose of this commentary is to highlight current research priorities of National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) regarding the development and testing of incentive-based interventions for the treatment of substance use disorders (SUDs). This manuscript summarizes the NIH Stage Model for behavioral intervention development, briefly reviews existing research on incentive-based treatments for SUDs that falls within the scope of DTMC at NIDA and highlights the development of digital therapeutics-based incentive interventions as an exemplar and high priority area. We briefly review how digital therapeutics approaches may address some common limitations to dissemination of incentive-based interventions and highlight opportunities for integrating incentive-based approaches into pharmacotherapy efficacy trials. Finally, we mention several related funding opportunities for researchers interested in developing incentive-based approaches for SUD treatment. The overall goal of this commentary is to inform the research community of current NIDA priority areas for intervention development and funding.
本文的目的是强调美国国立卫生研究院药物滥用研究所（NIDA）治疗学和医疗后果部（DTMC）目前关于激励干预措施开发和测试的研究重点，以治疗物质使用障碍（SUD）。本文总结了 NIH 行为干预发展阶段模型，简要回顾了 NIDA DTMC 范围内基于激励的 SUD 治疗的现有研究，并强调了基于数字治疗的激励干预措施的发展作为一个典范和高度优先领域。我们简要回顾了数字治疗方法如何解决激励干预措施传播的一些常见限制，并强调了将激励方法整合到药物治疗疗效试验中的机会。最后，我们提到了对开发 SUD 治疗激励方法感兴趣的研究人员的几个相关资助机会。本文的总体目标是让研究界了解 NIDA 当前的干预措施开发和资助重点领域。
